Abeona Therapeutics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABEO research report →
Companywww.abeonatherapeutics.com
Abeona Therapeutics Inc. , a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa.
- CEO
- Vishwas Seshadri
- IPO
- 1980
- Employees
- 136
- HQ
- Cleveland, NY, US
Price Chart
Valuation
- Market Cap
- $303.78M
- P/E
- 4.56
- P/S
- 20.89
- P/B
- 2.08
- EV/EBITDA
- 3.99
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 51.93%
- Op Margin
- -637.92%
- Net Margin
- 454.86%
- ROE
- 41.40%
- ROIC
- -50.87%
Growth & Income
- Revenue
- $5.82M · 0.00%
- Net Income
- $71.18M · 211.69%
- EPS
- $1.34 · 186.45%
- Op Income
- $-89,448,000
- FCF YoY
- -44.20%
Performance & Tape
- 52W High
- $7.54
- 52W Low
- $4.00
- 50D MA
- $5.13
- 200D MA
- $5.36
- Beta
- 1.34
- Avg Volume
- 1.26M
Get TickerSpark's AI analysis on ABEO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 26 | Crombez Eric | sell | 26,143 |
| May 11, 26 | Vasanthavada Madhav | sell | 5,548 |
| Apr 1, 26 | Goldan Keith A. | other | 32,751 |
| Apr 1, 26 | Goldan Keith A. | other | 0 |
| Mar 31, 26 | Seshadri Vishwas | sell | 29,985 |
| Mar 16, 26 | Vazzano Joseph Walter | sell | 785 |
| Feb 2, 26 | Silverstein Christine Berni | sell | 20,070 |
| Feb 2, 26 | Wuchterl Donald A. | sell | 14,814 |
| Feb 2, 26 | Crombez Eric | sell | 16,284 |
| Feb 2, 26 | Alland Leila | sell | 18,065 |
Our ABEO Coverage
We haven't published any research on ABEO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ABEO Report →